EDP Sciences logo
Authentification abonné
rechercher
Menu
Accueil Tous les numéros Volume 209 / Numéro 2 (2015) Biologie Aujourd'hui, 209 2 (2015) 161-166 Références
Accès gratuit
Numéro
Biologie Aujourd'hui
Volume 209, Numéro 2, 2015
Page(s) 161 - 166
Section Mécanismes de l’immunité anti-virale, défis thérapeutiques et développement de vaccins anti-sida
DOI https://doi.org/10.1051/jbio/2015019
Publié en ligne 29 octobre 2015
  • Alimonti, J.B., Ball, T.B., and Fowke, K.R. (2003). Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol, 84, 1649-1661. [CrossRef] [PubMed] [Google Scholar]
  • Barouch, D.H., and Picker, L.J. (2014). Novel vaccine vectors for HIV-1. Nat Rev Microbiol, 12, 765-771. [CrossRef] [PubMed] [Google Scholar]
  • Barouch, D.H., O’Brien, K.L., Simmons, N.L., King, S.L., Abbink, P., Maxfield, L.F., Sun, Y.H., La Porte, A., Riggs, A.M., Lynch, D.M., Clark, S.L., Backus, K., Perry, J.R., Seaman, M.S., Carville, A., Mansfield, K.G., Szinger, J.J., Fischer, W., Muldoon, M., and Korber, B. (2010). Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med, 16, 319-323. [CrossRef] [PubMed] [Google Scholar]
  • Barouch, D.H., Whitney, J.B., Moldt, B., Klein, F., Oliveira, T.Y., Liu, J., Stephenson, K.E., Chang, H.W., Shekhar, K., Gupta, S., Nkolola, J.P., Seaman, M.S., Smith, K.M., Borducchi, E.N., Cabral, C., Smith, J.Y., Blackmore, S., Sanisetty, S., Perry, J.R., Beck, M., Lewis, M.G., Rinaldi, W., Chakraborty, A.K., Poignard, P., Nussenzweig, M.C., and Burton, D.R. (2013). Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature, 503, 224-228. [PubMed] [Google Scholar]
  • Baychelier, F., Sennepin, A., Ermonval, M., Dorgham, K., Debré, P., and Vieillard, V. (2013). Identification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood, 122, 2935-2942. [CrossRef] [PubMed] [Google Scholar]
  • Benmira, S., Bhattacharya, V., and Schmid, M.L. (2010). An effective HIV vaccine: A combination of humoral and cellular immunity? Curr HIV Res, 8, 441-449. [CrossRef] [PubMed] [Google Scholar]
  • Bianchi, E., Joyce, J.G., Miller, M.D., Finnefrock, A.C., Liang, X., Finotto, M., Ingallinella, P., McKenna, P., Citron, M., Ottinger, E., Hepler, R.W., Hrin, R., Nahas, D., Wu, C., Montefiori, D., Shiver, J.W., Pessi, A., and Kim, P.S. (2010). Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates. Proc Natl Acad Sci USA, 107, 10655-10660. [CrossRef] [Google Scholar]
  • Corti, D., and Lanzavecchia, A. (2013). Broadly neutralizing antiviral antibodies. Annu Rev Immunol, 31, 705-742. [CrossRef] [PubMed] [Google Scholar]
  • Curriu, M., Fausther-Bovendo, H., Pernas, M., Massanella, M., Carrillo, J., Cabrera, C., López-Galíndez, C., Clotet, B., Debré, P., Vieillard, V., and Blanco, J. (2012). Viremic HIV infected individuals with high CD4 T cells and functional envelope proteins show anti-gp41 antibodies with unique specificity and function. PloS One, 7, e30330. [CrossRef] [PubMed] [Google Scholar]
  • Derdeyn, C.A., and Silvestri, G. (2005). Viral and host factors in the pathogenesis of HIV infection, Curr Opin Immunol, 17, 366-373. [CrossRef] [PubMed] [Google Scholar]
  • Fausther-Bovendo, H., Vieillard, V., Sagan, S., Bismuth, G., and Debré, P. (2010). HIV gp41 engages gC1qR on CD4+ T cells to induce the expression of an NK ligand through the PIP3/H2O2 pathway. PLoS Pathog, 6, e1000975. [CrossRef] [PubMed] [Google Scholar]
  • Fenyö, E.M., Heath, A., Dispinseri, S., Holmes, H., Lusso, P., Zolla-Pazner, S., Donners, H., Heyndrickx, L., Alcami, J., Bongertz, V., Jassoy, C., Malnati, M., Montefiori, D., Moog, C., Morris, L., Osmanov, S., Polonis, V., Sattentau, Q., Schuitemaker, H., Sutthent, R., Wrin, T., and Scarlatti, G. (2009). International network for comparison of HIV neutralization assays: the NeutNet report. PloS One, 4, e4505. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Golding, H., Shearer, G.M., Hillman, K., Lucas, P., Manischewitz, J., Zajac, R.A., Clerici, M., Gress, R.E., Boswell, R.N., and Golding, B. (1989). Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest, 83, 1430. [CrossRef] [PubMed] [Google Scholar]
  • González, N., Alvarez, A., and Alcamí, J. (2010). Broadly neutralizing antibodies and their significance for HIV-1 vaccines. Curr HIV, 8, 602-612. [CrossRef] [Google Scholar]
  • Huang, J., Kang, B.H., Pancera, M., Lee, J.H., Tong, T., Feng, Y., Imamichi, H., Georgiev, I.S., Chuang, G.Y., Druz, A., Doria-Rose, N.A., Laub, L., Sliepen, K., van Gils, M.J., de la Peña, A.T., Derking, R., Klasse, P.J., Migueles, S.A., Bailer, R.T., Alam, M., Pugach, P., Haynes, B.F., Wyatt, R.T., Sanders, R.W., Binley, J.M., Ward, A.B., Mascola, J.R., Kwong, P.D., and Connors, M. (2014). Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. Nature, 515, 138-142. [CrossRef] [PubMed] [Google Scholar]
  • Karlsson, I., Brandt, L., Vinner, L., Kromann, I., Andreasen, L.V., Andersen, P., Gerstoft, J., Kronborg, G., and Fomsgaard, A. (2013). Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clin Immunol, 146, 120-130. [CrossRef] [PubMed] [Google Scholar]
  • Manrique, A., Rusert, P., Joos, B., Fischer, M., Kuster, H., Leemann, C., Niederöst, B., Weber, R., Stiegler, G., Katinger, H., Günthard, H.F., and Trkola, A. (2007). In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol, 81, 8793-8808. [CrossRef] [PubMed] [Google Scholar]
  • McCoy, L.E., and Weiss, R.A. (2013). Neutralizing antibodies to HIV-1 induced by immunization. J Exp Med, 210, 209-223. [CrossRef] [MathSciNet] [PubMed] [Google Scholar]
  • Mikell, I., Sather, D.N., Kalams, S.A., Altfeld, M., Alter, G., and Stamatatos, L. (2011). Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1. PLoS Pathog, 7, e1001251. [CrossRef] [PubMed] [Google Scholar]
  • Nakowitsch, S., Quendler, H., Fekete, H., Kunert, R., Katinger, H., and Stiegler, G. (2005). HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies. AIDS, 19, 1957-1966 [CrossRef] [PubMed] [Google Scholar]
  • Petitdemange, C., Achour, A., Dispinseri, S., Malet, I., Sennepin, A., Ho Tsong Fang, R., Crouzet, J., Marcelin, A.G., Calvez, V., Scarlatti, G., Debré, P., and Vieillard, V. (2013). A single amino-acid change in a highly conserved motif of gp41 elicits HIV-1 neutralization and protects against CD4 depletion. Clin Infect Dis, 57, 745-755. [CrossRef] [PubMed] [Google Scholar]
  • Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J.G., Francis, D.P., Stablein, D., Birx, D.L., Chunsuttiwat, S., Khamboonruang, C., Thongcharoen, P., Robb, M.L., Michael, N.L., Kunasol, P., and Kim, J.H. MOPH-TAVEG Investigators. (2009). Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. N England J Med, 361, 2209-2220. [Google Scholar]
  • Stiegler, G., Kunert, R., Purtscher, M., Wolbank, S., Voglauer, R., Steindl, F., and Katinger, H. (2001). A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses, 17, 1757-1765. [CrossRef] [PubMed] [Google Scholar]
  • Tsong Fang, R. Ho, Launay, O., Rouzioux, C., Autran, B., Capeau, J., Mélard, A., Marcu, M., Calin, R., Bodilis, H., Crouzet, J., Vieillard, V., Debré, P., Gharakhanian, S., and Katlama, C. (2015). VAC-3S, an Immunotherapeutic HIV Vaccine decreases total HIV DNA and increases CD4/CD8 ratio: Phase I Final Results. International AIDS Society HIV, Cure Symposium. 2015, 18−19 July, Vancouver, Canada. Poster PE66. [Google Scholar]
  • Vieillard, V., Strominger, J.L., and Debré, P. (2005). NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand. Proc Natl Acad Sci USA, 102, 10981-10986. [CrossRef] [Google Scholar]
  • Vieillard, V., Le Grand, R., Dausset, J., and Debré, P. (2008a). A vaccine strategy against AIDS: an HIV gp41 peptide immunization prevents NKp44L expression and CD4+ T cell depletion in SHIV-infected macaques. Proc Natl Acad Sci USA, 105, 2100-2104. [CrossRef] [Google Scholar]
  • Vieillard, V., Habib, R.E., Brochard, P., Delache, B., Bovendo, H.F., Calvo, J., Morin, J., Picq, I., Martinon, F., Vaslin, B., Le Grand, R., and Debré, P. (2008b). CCR5 or CXCR4 use influences the relationship between CD4 cell depletion, NKp44L expression and NK cytotoxicity in SHIV-infected macaques. AIDS, 22, 185-192. [CrossRef] [PubMed] [Google Scholar]
  • Vieillard, V., Dereuddre-Bosquet, N., Mangeot-Méderlé, I., Le Grand, R., and Debré, P. (2012). An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques. Vaccine, 30, 6883-91. [CrossRef] [PubMed] [Google Scholar]
  • Walker, L.M., and Burton, D.R. (2010). Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr Opin Immunol, 22, 358-366. [CrossRef] [PubMed] [Google Scholar]
  • Wu, X., Yang, Z.Y., Li, Y., Hogerkorp, C.M., Schief, W.R., Seaman, M.S., Zhou, T., Schmidt, S.D., Wu, L., Xu, L., Longo, N.S., McKee, K., O’Dell, S., Louder, M.K., Wycuff, D.L., Feng, Y., Nason, M., Doria-Rose, N., Connors, M., Kwong, P.D., Roederer, M., Wyatt, R.T., Nabel, G.J., and Mascola, J.R. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science, 329, 856-861. [CrossRef] [PubMed] [Google Scholar]
  • Zhou, T., Georgiev, I., Wu, X., Yang, Z.Y., Dai, K., Finzi, A., Kwon, Y.D., Scheid, J.F., Shi, W., Xu, L., Yang, Y., Zhu, J., Nussenzweig, M.C., Sodroski, J., Shapiro, L., Nabel, G.J., Mascola, J.R., and Kwong, P.D. (2010). Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science, 329, 811-817. [CrossRef] [PubMed] [Google Scholar]
  • Zolla-Pazner, S., and Cardozo, T. (2010). Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol, 10, 527-535. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.